Showing 941-950 of 20877 results for "".
- More Negative Sentinel Nodes Didn’t Improve Breast Cancer Outcomeshttps://reachmd.com/news/more-negative-sentinel-nodes-didnt-improve-breast-cancer-outcomes/2488299/Key Takeaways In a 1,551-patient single-center cohort of cT1-2N0M0 breast cancer with negative sentinel nodes, 5-year DFS and OS did not differ significantly across groups with 1-3, 4-6, or at least 7 nodes removed. Adjusted analyses did not identify sentinel-node co
- RHOB Signaling May Explain Nocturnal IOP Rise in Glaucomahttps://reachmd.com/news/rhob-signaling-may-explain-nocturnal-iop-rise-in-glaucoma/2488300/Key Takeaways In a preclinical Communications Biology study using human trabecular meshwork cells and mice, norepinephrine signaling was linked to nocturnal IOP elevation through RHOB in the eye's drainage pathway. Shared gene-expre
- Capnography Missed PaCO2 in Most Prehospital Intubationshttps://reachmd.com/news/capnography-paco2-prehospital-intubations/2488292/Key Takeaways In a single Southern Finland HEMS cohort of critically ill patients after prehospital emergency anesthesia and intubation, most had a PaCO2-EtCO2 gradient above the assumed threshold. Overall agreement between arterial and end-tidal carbon dioxide was w
- Upadacitinib Shows Sustained Responses in PsA After Prior TNF Inhibitor: Analysishttps://reachmd.com/news/upadacitinib-shows-sustained-responses-in-psa-after-prior-tnf-inhibitor-analysis/2488287/A post hoc analysis of SELECT-PsA 2 found sustained responses with upadacitinib 15 mg once daily through 152 weeks among patients with psoriatic arthritis (PsA) previously exposed to 1 tumor necrosis factor inhibitor (TNFi). Published in RMD Open, the analysis included 195 patient
- IgA Nephropathy Linked to Cardiometabolic Genetic Overlaphttps://reachmd.com/news/iga-nephropathy-cardiometabolic-genetic-overlap/2488265/Key Takeaways An integrative genomic analysis of IgA nephropathy and related vascular, metabolic, and immune traits reported significant shared inherited susceptibility across multiple vascular and metabolic phenotypes. Risk-factor phenotypes showed stronger overlap
- ICU Pain Was Common and Persistent in a 711-Patient Cohorthttps://reachmd.com/news/icu-pain-was-common-and-persistent-in-a-711-patient-cohort/2488242/Key Takeaways Among mixed adult ICU patients in four ICUs across two tertiary university hospitals in Finland, pain at rest was commonly documented during ICU stay. Average daily pain prevalence was 43.7%, and the burden did not decline during follow-up. Fem
- Cuttlefish Ink-Derived Microneedles Show Potential for Vitiligo Repigmentationhttps://reachmd.com/news/cuttlefish-ink-derived-microneedles-show-potential-for-vitiligo-repigmentation/2488260/Researchers have developed a fast-dissolving microneedle platform designed to address oxidative stress, inflammation, melanocyte loss, and depigmentation in vitiligo, according to a preclinical study published in Marine Life Scie
- Vision Loss After Nonsurgical Rhinoplasty Often Immediate: Systematic Reviewhttps://reachmd.com/news/vision-loss-after-nonsurgical-rhinoplasty-often-immediate-systematic-review/2488257/Vision loss following nonsurgical rhinoplasty with dermal fillers is rare but can result in persistent visual impairment, according to findings from a systematic review of published cases. Vision Los
- Maternal and Infant Skin Microbiomes Show Distinct but Connected Developmenthttps://reachmd.com/news/maternal-and-infant-skin-microbiomes-show-distinct-but-connected-development/2488255/The skin microbiomes of mothers and their infants appear to be closely connected during early life, although infant microbial diversity follows its own developmental trajectory, according to a recent longitudinal study published in Experimental Dermatology. Researchers for the stu
- Brepocitinib Associated with Improved Skin Outcomes in Dermatomyositishttps://reachmd.com/news/brepocitinib-skin-outcomes-dermatomyositis/2488232/Key Takeaways In adults with dermatomyositis in the phase 3 VALOR trial, brepocitinib 30 mg was associated with better skin-specific outcomes than placebo. Improvement in cutaneous disease activity was seen by week 4 and was reported through week 52 with brepocitinib